Differentiation of Adipose-Derived Stromal/Stem Cells into Osteocytes.
de Beer J., Pepper MS.
Laboratory Study, published in Methods Mol Biol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Methods Mol Biol (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40445290
- DOI
- 10.1007/978-1-0716-4607-6_17
- Citations
- 1
Abstract (original English)
Osteogenesis, which refers to the formation of bone tissue, can be studied in vitro to elucidate the mechanisms of bone development, identify key factors and cytokines, and enhance potential regenerative medicine applications in tissue engineering and transplantation. Adipose-derived stromal/stem cells (ASCs) are particularly promising for these studies due to their capacity to differentiate into various mesodermal lineage cells, including osteoblasts. To induce osteogenic differentiation, ASCs are cultured in a complete growth medium (CGM) supplemented with β-glycerophosphate, ascorbate-2-phosphate and dexamethasone over a period of at least 3 weeks. Osteogenic differentiation can be assessed through the deposition of hydroxyapatite, a key component of mineralized bone matrix, and the activity of alkaline phosphatase, an enzyme crucial for matrix calcification. This study provides a protocol for differentiating ASCs into osteoblasts using osteogenic differentiation medium (ODM) and evaluating the differentiation using Alizarin Red S (ARS) staining and alkaline phosphatase (ALP) assays. The methodology includes the preparation of CGM and ODM, as well as the specific procedures for ARS staining and ALP activity assays. The ARS staining involves fixation of cells, staining, and quantification of hydroxyapatite deposition, while the ALP assay measures enzyme activity. Both assays
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.